Galactose-1-Phosphate Uridyltransferase Deficiency (Galactosemia) Treatment & Management
- Author: Gerard T Berry, MD; Chief Editor: Bruce Buehler, MD more...
Medical Care
- The mainstay of medical care in the postnatal period is to immediately discontinue ingestion of lactose-containing formula.
- This ameliorates the acute toxicity associated with the neonatal period but does not prevent all long-term complications.
- Clotting abnormalities may be cryptic and require fresh frozen plasma treatments.[10]
Consultations
- Refer children to appropriate language and speech centers to optimize treatment for learning problems.
- Refer women to an endocrinologist or reproductive gynecologist for appropriate treatment for ovarian failure.
- No standardized treatment for short stature has been established, and the etiology is unknown in many instances.
- Because dietary therapy is necessary, refer patients to a dietitian who has experience with metabolic disorders.
- Consultation with a biochemical geneticist (ie, metabolic disease specialist) is advisable for diagnostic laboratory evaluation, monitoring, and clinical care for patients with galactosemia.
Diet
- Prescribe a galactose-restricted diet for infants who are galactosemic. Older patients may tolerate lactose better than infants. The restriction of milk intake throughout life is controversial. However, most metabolic specialists support a life-long diet therapy.[7]
- Totally eliminating galactose is difficult because it is present in a wide variety of foods (eg, infant foods, fruits, vegetables), especially in the macromolecular form.
- Dietary restrictions during pregnancy, as well as prospectively during postnatal life, may have no effect on long-term complications of an affected fetus.
Berry GT, Segal S and Gitzelmann R. Disorders of Galactose Metabolism. In: Fernandes J, Saudubray M, van den Berghe G, Walter JH. Inborn Metabolic Diseases - Diagnosis and Treatment. 4. New York, NY: Springer-Verlag, Inc; 2006.
Segal S. Galactosemia unsolved. Eur J Pediatr. 1995;154(7 Suppl 2):S97-102. [Medline].
Fridovich-Keil J, Walter. Galactosemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill Medical Publishing Division; 2008:72.
Mason HH, Turner ME. Chronic galactosemia: report of case with studies on carbohydrates. Am J Dis Child. 1935;50:359-74.
Komrower GM, Lee DH. Long-term follow-up of galactosaemia. Arch Dis Child. Jun 1970;45(241):367-73. [Medline].
Waggoner DD, Buist NR, Donnell GN. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis. 1990;13(6):802-18. [Medline].
Walter JH, Collins JE, Leonard JV. Recommendations for the management of galactosaemia. UK Galactosaemia Steering Group. Arch Dis Child. Jan 1999;80(1):93-6. [Medline].
Garden AS, Davidson DC. Recommendations for the management of galactosaemia. Arch Dis Child. Mar 2000;82(3):266. [Medline].
Antshel KM, Epstein IO, Waisbren SE. Cognitive strengths and weaknesses in children and adolescents homozygous for the galactosemia Q188R mutation: a descriptive study. Neuropsychology. Oct 2004;18(4):658-64. [Medline].
Levy HL, Brown AE, Williams SE, de Juan E Jr. Vitreous hemorrhage as an ophthalmic complication of galactosemia. J Pediatr. Dec 1996;129(6):922-5. [Medline].
Waisbren SE, Norman TR, Schnell RR, Levy HL. Speech and language deficits in early-treated children with galactosemia. J Pediatr. Jan 1983;102(1):75-7. [Medline].
Nelson CD, Waggoner DD, Donnell GN, et al. Verbal dyspraxia in treated galactosemia. Pediatrics. Aug 1991;88(2):346-50. [Medline].
Potter NL, Lazarus JA, Johnson JM, Steiner RD, Shriberg LD. Correlates of language impairment in children with galactosaemia. J Inherit Metab Dis. Aug 2008;31(4):524-32. [Medline].
Hoffmann B, Wendel U, Schweitzer-Krantz S. Cross-sectional analysis of speech and cognitive performance in 32 patients with classic galactosemia. J Inherit Metab Dis. Apr 2011;34(2):421-7. [Medline].
Timmers I, van den Hurk J, Di Salle F, Rubio-Gozalbo ME, Jansma BM. Language production and working memory in classic galactosemia from a cognitive neuroscience perspective: future research directions. J Inherit Metab Dis. Apr 2011;34(2):367-76. [Medline]. [Full Text].
ten Hoedt AE, Maurice-Stam H, Boelen CC, Rubio-Gozalbo ME, van Spronsen FJ, Wijburg FA, et al. Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life. J Inherit Metab Dis. Apr 2011;34(2):391-8. [Medline]. [Full Text].
Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med. Apr 23 1981;304(17):994-8. [Medline].
Guerrero NV, Singh RH, Manatunga A, Berry GT, Steiner RD, Elsas LJ 2nd. Risk factors for premature ovarian failure in females with galactosemia. J Pediatr. Dec 2000;137(6):833-41. [Medline].
Forges T, Monnier-Barbarino P. [Premature ovarian failure in galactosaemia: pathophysiology and clinical management]. Pathol Biol (Paris). Feb 2003;51(1):47-56. [Medline].
Gubbels CS, Land JA, Rubio-Gozalbo ME. Fertility and impact of pregnancies on the mother and child in classic galactosemia. Obstet Gynecol Surv. May 2008;63(5):334-43. [Medline].
Schweitzer S, Shin Y, Jakobs C, Brodehl J. Long-term outcome in 134 patients with galactosaemia. Eur J Pediatr. Jan 1993;152(1):36-43. [Medline].
Schadewaldt P, Lilburn M, Wendel U, Lee P. Unexpected outcome in untreated galactosaemia. Molecular Genetics and Metabolism. 2004;81:255-57.
Panis B, Bakker JA, Sels JP, Spaapen LJ, van Loon LJ, Rubio-Gozalbo ME. Untreated classical galactosemia patient with mild phenotype. Mol Genet Metab. Nov 2006;89(3):277-9. [Medline].
Elsas L, Fridovich-Keil J, Leslie N. Galactosemia: a molecular approach to the enigma. In: International Pediatrics. 1993:101-9.
Elsas LJ 2nd, Langley S, Paulk EM, et al. A molecular approach to galactosemia. Eur J Pediatr. 1995;154(7 Suppl 2):S21-7. [Medline].
Hennermann JB, Schadewaldt P, Vetter B, Shin YS, Mönch E, Klein J. Features and outcome of galactokinase deficiency in children diagnosed by newborn screening. J Inherit Metab Dis. Apr 2011;34(2):399-407. [Medline].
Arn PH. Galactosemia. Curr Treat Options Neurol. Jul 2003;5(4):343-345. [Medline].
Berry GT. Galactosemia and amenorrhea in the adolescent. Ann N Y Acad Sci. 2008;1135:112-7. [Medline].
Bosch AM. Classical galactosaemia revisited. J Inherit Metab Dis. Aug 2006;29(4):516-25. [Medline].
Forges T, Monnier-Barbarino P, Leheup B, Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update. Sep-Oct 2006;12(5):573-84. [Medline].
Gibson JB. Gonadal function in galactosemics and in galactose-intoxicated animals. Eur J Pediatr. 1995;154(7 Suppl 2):S14-20. [Medline].
Holton JB, Leonard JV. Clouds still gathering over galactosaemia. Lancet. Nov 5 1994;344(8932):1242-3. [Medline].
Komrower GM. Clouds over galactosemia. Lancet. Jan 22 1983;1(8317):190. [Medline].
Komrower GM. Galactosaemia - thirty years on the experience of a generation. J Inherit Metab Dis. 1982;5(Suppl 2):96-104.
Leslie ND. Insights into the pathogenesis of galactosemia. Annu Rev Nutr. 2003;23:59-80. [Medline].
Ridel KR, Leslie ND, Gilbert DL. An updated review of the long-term neurological effects of galactosemia. Pediatr Neurol. Sep 2005;33(3):153-61. [Medline].
Schweitzer-Krantz S. Early diagnosis of inherited metabolic disorders towards improving outcome: the controversial issue of galactosaemia. Eur J Pediatr. Dec 2003;162 Suppl 1:S50-3. [Medline].
Segal S. Komrower Lecture. Galactosaemia today: the enigma and the challenge. J Inherit Metab Dis. Aug 1998;21(5):455-71. [Medline].
Segal S, Berry G. Disorders of galactose metabolism. In: The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill; 1995:967-1000.

